1. Home
  2. ARTL vs FEED Comparison

ARTL vs FEED Comparison

Compare ARTL & FEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$3.35

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

FEED

ENvue Medical Inc. Common Stock

N/A

Current Price

$1.18

Market Cap

4.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARTL
FEED
Founded
2011
2003
Country
United States
United States
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARTL
FEED
Price
$3.35
$1.18
Analyst Decision
Hold
Analyst Count
2
0
Target Price
N/A
N/A
AVG Volume (30 Days)
502.4K
195.7K
Earning Date
05-13-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.99
52 Week High
$28.60
$6.09

Technical Indicators

Market Signals
Indicator
ARTL
FEED
Relative Strength Index (RSI) 39.23 33.18
Support Level $3.05 $1.02
Resistance Level $3.67 $2.95
Average True Range (ATR) 0.45 0.09
MACD -0.25 -0.03
Stochastic Oscillator 5.57 10.12

Price Performance

Historical Comparison
ARTL
FEED

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: